U.S. markets closed

Alkermes plc (ALKS)

NasdaqGS - NasdaqGS Precio en tiempo real. Divisa en USD.
Añadir a la lista de seguimiento
24.26+0.19 (+0.79%)
Al cierre: 04:00PM EDT
24.26 -0.01 (-0.04%)
Fuera de horario: 04:02PM EDT

Alkermes plc

Connaught House
1 Burlington Road Dublin 4
Dublin D04 C5Y6
Ireland
353 1 772 8000
https://www.alkermes.com

Sector(es)Healthcare
IndustriaDrug Manufacturers - Specialty & Generic
Empleados a tiempo completo2,100

Ejecutivos clave

NombreTítuloPagarEjecutadoAño de nacimiento
Mr. Richard F. PopsChairman & CEO2.61MN/D1962
Mr. Blair C. JacksonInterim Principal Financial Officer, Executive VP, Chief Risk Officer & COO1.17MN/D1973
Mr. David Joseph GaffinExecutive VP, Chief Legal Officer, Chief Compliance Officer & Secretary1.15MN/D1972
Mr. Iain Michael BrownSenior VP & CFO (Leave of Absence)950.88kN/D1969
Dr. Craig C. Hopkinson M.D.Executive VP of Research & Development and Chief Medical Officer1.24MN/D1968
Dr. Floyd E. Bloom M.D.Founder57.73kN/D1937
Mr. Samuel J. ParisiInterim Principal Accounting Officer & VP of FinanceN/DN/D1975
Mr. Thomas HarveyChief Information Officer & Senior VP of ITN/DN/DN/D
Ms. Sandra CoombsSenior Vice President of Corporate Affairs & Investor RelationsN/DN/DN/D
Mr. Stephen SchiavoSenior Vice President of Human ResourcesN/DN/DN/D
Los importes son a partir de 31 de diciembre de 2023 y los valores de compensación son para el último año fiscal que finaliza en esa fecha. Pago corresponde al salario, las bonificaciones, etc. Ejecutado corresponde al valor de las opciones ejecutadas durante el año fiscal. Divisa en USD.

Descripción

Alkermes plc, a biopharmaceutical company, researches, develops, and commercializes pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. It has a portfolio of proprietary commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; and LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.

Gestión corporativa

La calificación ISS Governance QuickScore de Alkermes plc a partir del 1 de abril de 2024 es 3. Las puntuaciones principales son Auditoría: 1; Junta: 6; Derechos del accionista: 3; Compensación: 4.

Las puntuaciones de la gestión corporativa son cortesía de Servicios de accionistas institucionales (ISS). Las puntuaciones indican una posición decil en relación con el índice o la región. Una puntuación decil 1 indica que el riesgo de gestión es menor, mientras que una puntuación decil 10 indica que el riesgo de gestión es mayor.